13F Holdings
中文EN

HCM HUTCHMED (China) Ltd

Pharmaceutical Preparations · Nasdaq · SEC CIK 1648257

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-13.0%
TTM net income YoY1,111.0%
TTM EPS YoY1,200.0%
Revenue 3-yr CAGR8.8%
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-7.1%
Net margin83.3%
FCF margin-14.4%
EBITDA margin-4.7%

Returns

ROE45.7%
ROA30.2%
ROIC (approx.)-3.5%
Asset turnover0.36x

Leverage & solvency

Liabilities / assets28.6%
Debt / equity0.08x
Current ratio4.96x
Interest coverage-13.67x

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio34.5%
Payout ratio—
Capex / revenue2.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2019Q4*2019-12-312019Q3*2019-09-302019Q2*2019-06-302019Q12019-03-312018Q4*2018-12-312018Q3*2018-09-302018Q2*2018-06-302018Q12018-03-31
Income statement
Revenue$53.34M$49.35M$50.03M$52.17M$53.11M$58.81M$49.85M$52.34M
R&D expense$37.45M$31.45M$36.01M$33.28M$25.43M$28.68M$31.39M$28.66M
SG&A expense$8.92M$11.46M$8.63M$10.20M$8.94M$7.42M$7.53M$7.02M
Operating income-$38.43M-$35.94M-$35.96M-$36.05M-$24.17M-$14.79M-$28.66M-$25.02M
Interest expense$259,000$83,000$428,000$260,000$281,000$284,000$238,000$206,000
Pretax income-$38.47M-$34.34M-$33.39M-$34.91M-$23.06M-$13.10M-$26.62M-$23.87M
Income tax$715,000$97,000$1.15M$1.31M$969,000$315,000$1.11M$1.56M
Net income-$29.56M-$31.09M-$25.48M-$19.89M-$16.54M-$25.58M-$20.96M-$11.73M
EBITDA-$37.13M-$34.71M-$34.76M-$34.84M-$23.14M-$13.91M-$27.81M-$24.19M
EPS (basic)———-0.03———-0.02
EPS (diluted)———-0.03———-0.02
Weighted avg. shares (diluted)———665.47M———663.84M
Banking
Deposits$1.78M$1.27M$1.30M$1.90M$1.23M—$1.39M—
Balance sheet
Cash & equivalents$121.16M$97.08M$83.36M$91.69M$86.04M$115.59M$75.33M$78.10M
Short-term investments$96.01M$104.49M$153.93M$180.17M$214.91M—$247.16M—
Receivables$41.41M$40.33M$42.76M$42.27M$40.18M—$44.42M—
Inventory$16.21M$15.65M$14.22M$17.61M$12.31M—$9.79M—
Current assets$317.02M$277.08M$309.50M$349.99M$370.54M—$394.68M—
PP&E, net$20.86M$18.53M$17.67M$17.04M$16.62M—$14.42M—
Goodwill$3.11M$3.09M$3.19M$3.26M$3.19M—$3.36M—
Intangibles$275,000$288,000$315,000$340,000$347,000—$403,000—
Total assets$465.12M$454.09M$495.21M$539.30M$532.12M—$577.94M—
Current liabilities$113.10M$105.34M$110.61M$101.33M$85.48M—$84.58M—
Long-term debt$26.82M$0$0$26.76M$26.74M—$26.69M—
Total debt$26.82M$0$0$26.76M$26.74M—$26.69M—
Total liabilities$152.22M$116.31M$122.18M$138.94M$119.86M—$120.10M—
Shareholders' equity$288.01M$313.52M$347.89M$375.77M$389.00M$424.70M$431.73M$478.40M
Net debt-$94.34M-$97.08M-$83.36M-$64.93M-$59.30M—-$48.64M—
Cash flow statement
Operating cash flow-$17.39M-$33.48M-$1.12M-$28.92M-$13.94M-$315,000$12.24M-$30.84M
Capital expenditure$2.95M$1.77M$2.49M$1.36M$2.93M$1.35M$761,000$1.32M
Free cash flow-$20.34M-$35.25M-$3.61M-$30.28M-$16.87M-$1.67M$11.48M-$32.16M
Investing cash flow$14.22M$47.67M$23.76M$33.38M-$15.26M$43.22M-$11.92M$27.71M
Financing cash flow$26.90M$1.12M-$29.17M-$346,000-$413,000$24,000-$2.61M-$5.23M
Depreciation & amortization$1.31M$1.23M$1.20M$1.21M$1.03M$874,000$854,000$834,000
Share buybacks$0$0$0$346,000$0$0$0$5.45M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.